JAIDS: Youth-Specific Considerations in the Development of Preexposure Prophylaxis, Microbicide, and Vaccine Research Trials

Full article - free [includes a section on rectal microbicides]

This article is one of several from the July 1, 2010 - Volume 54 - Supplement 1, "Inclusion of Adolescents and Young Adults in Biomedical HIV Prevention Research" - click here to read the rest
 

JAIDS Journal of Acquired Immune Deficiency Syndromes:

1 July 2010 - Volume 54 - Issue - pp S31-S42

doi: 10.1097/QAI.0b013e3181e3a922

Supplement Article

Rudy, Bret J MD; Kapogiannis, Bill G MD; Lally, Michelle A MD, MSc; Gray, Glenda E MBBCH, FCPaeds(SA); Bekker, Linda-Gail MBCHB, FCP, PhD; Krogstad, Paul MD; McGowan, Ian MD, PhD

Abstract:

Preventing HIV infection in adolescents and young adults will require a multimodal targeted approach, including individual-directed behavioral risk reduction, community-level structural change, and biomedical interventions to prevent sexual transmission. Trials testing biomedical interventions to prevent HIV transmission will require special attention in this population due to the unique psychosocial and physiologic characteristics that differentiate them from older populations. For example, microbicide research will need to consider acceptability, dosing requirements, and coinfection rates that are unique to this population. Preexposure prophylaxis studies also will need to consider potential unique psychosocial issues such as sexual disinhibition and acceptability as well as unique pharmacokinetic parameters of antiretroviral agents. Vaccine trials also face unique issues with this population, including attitudes toward vaccines, risks related to false-positive HIV tests related to vaccine, and different immune responses based on more robust immunity. In this article, we will discuss issues around implementing each of these biomedical prevention modalities in trials among adolescents and young adults to help to guide future successful research targeting this population.

Read the whole article.